Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 111.5 Billion KRW | 163.98% |
| 2022 | 42.23 Billion KRW | 72.37% |
| 2021 | 24.5 Billion KRW | 1.48% |
| 2020 | 24.14 Billion KRW | 9.73% |
| 2019 | 22 Billion KRW | 245.24% |
| 2018 | -15.15 Billion KRW | -147.98% |
| 2017 | 31.58 Billion KRW | 17.1% |
| 2016 | 26.96 Billion KRW | -37.18% |
| 2015 | 42.93 Billion KRW | 36.09% |
| 2014 | 31.54 Billion KRW | -45.99% |
| 2013 | 58.39 Billion KRW | 71.36% |
| 2012 | 34.07 Billion KRW | -32.09% |
| 2011 | 50.18 Billion KRW | 185.75% |
| 2010 | 17.56 Billion KRW | -64.5% |
| 2009 | 49.46 Billion KRW | 50.21% |
| 2008 | 32.93 Billion KRW | -44.14% |
| 2007 | 58.94 Billion KRW | 21.49% |
| 2006 | 48.52 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 8.14 Billion KRW | -87.66% |
| 2024 Q2 | 1.14 Billion KRW | -86.0% |
| 2023 FY | 111.5 Billion KRW | 163.98% |
| 2023 Q1 | 15.4 Billion KRW | 235.52% |
| 2023 Q4 | 66 Billion KRW | 323.71% |
| 2023 Q3 | 15.57 Billion KRW | -37.04% |
| 2023 Q2 | 24.74 Billion KRW | 60.57% |
| 2022 Q3 | 20.5 Billion KRW | 17.37% |
| 2022 Q4 | -11.37 Billion KRW | -155.46% |
| 2022 FY | 42.23 Billion KRW | 72.37% |
| 2022 Q2 | 17.46 Billion KRW | 28.26% |
| 2022 Q1 | 13.61 Billion KRW | -55.6% |
| 2021 Q3 | 10.97 Billion KRW | 79.18% |
| 2021 Q1 | -23.1 Billion KRW | -231.65% |
| 2021 Q2 | 6.12 Billion KRW | 126.5% |
| 2021 Q4 | 30.67 Billion KRW | 179.6% |
| 2021 FY | 24.5 Billion KRW | 1.48% |
| 2020 Q4 | 17.55 Billion KRW | 630.26% |
| 2020 Q1 | 676.37 Million KRW | -78.47% |
| 2020 FY | 24.14 Billion KRW | 9.73% |
| 2020 Q3 | 2.4 Billion KRW | 130.51% |
| 2020 Q2 | -7.87 Billion KRW | -1264.76% |
| 2019 FY | 22 Billion KRW | 245.24% |
| 2019 Q1 | 5.85 Billion KRW | 121.77% |
| 2019 Q3 | 1.58 Billion KRW | -86.18% |
| 2019 Q4 | 3.14 Billion KRW | 98.81% |
| 2019 Q2 | 11.43 Billion KRW | 95.27% |
| 2018 Q3 | 3.28 Billion KRW | -41.99% |
| 2018 FY | -15.15 Billion KRW | -147.98% |
| 2018 Q1 | 2.78 Billion KRW | -64.69% |
| 2018 Q2 | 5.66 Billion KRW | 103.71% |
| 2018 Q4 | -26.88 Billion KRW | -918.01% |
| 2017 Q1 | 3.28 Billion KRW | -78.96% |
| 2017 FY | 31.58 Billion KRW | 17.1% |
| 2017 Q4 | 7.87 Billion KRW | -12.22% |
| 2017 Q3 | 8.97 Billion KRW | -21.61% |
| 2017 Q2 | 11.44 Billion KRW | 248.46% |
| 2016 FY | 26.96 Billion KRW | -37.18% |
| 2016 Q1 | 2.82 Billion KRW | -66.2% |
| 2016 Q4 | 15.61 Billion KRW | 280.01% |
| 2016 Q3 | 4.1 Billion KRW | -7.17% |
| 2016 Q2 | 4.42 Billion KRW | 56.85% |
| 2015 FY | 42.93 Billion KRW | 36.09% |
| 2015 Q1 | 11.33 Billion KRW | 12.54% |
| 2015 Q2 | 12.81 Billion KRW | 13.04% |
| 2015 Q3 | 10.42 Billion KRW | -18.66% |
| 2015 Q4 | 8.34 Billion KRW | -19.93% |
| 2014 Q1 | 12.32 Billion KRW | 27.0% |
| 2014 FY | 31.54 Billion KRW | -45.99% |
| 2014 Q3 | -5.65 Billion KRW | -138.22% |
| 2014 Q4 | 10.07 Billion KRW | 278.15% |
| 2014 Q2 | 14.79 Billion KRW | 20.03% |
| 2013 Q2 | 16.9 Billion KRW | 41.83% |
| 2013 Q1 | 11.91 Billion KRW | 4.15% |
| 2013 FY | 58.39 Billion KRW | 71.36% |
| 2013 Q4 | 9.7 Billion KRW | -51.15% |
| 2013 Q3 | 19.86 Billion KRW | 17.53% |
| 2012 FY | 34.07 Billion KRW | -32.09% |
| 2012 Q1 | 11.9 Billion KRW | 0.0% |
| 2012 Q2 | 4.71 Billion KRW | -60.4% |
| 2012 Q3 | 6.46 Billion KRW | 37.26% |
| 2012 Q4 | 11.44 Billion KRW | 76.9% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 50.18 Billion KRW | 185.75% |
| 2011 Q3 | 14.49 Billion KRW | -17.31% |
| 2011 Q2 | 17.52 Billion KRW | 27.62% |
| 2011 Q1 | 13.73 Billion KRW | 0.0% |
| 2010 Q2 | -11.14 Billion KRW | -171.57% |
| 2010 FY | 17.56 Billion KRW | -64.5% |
| 2010 Q3 | 15.41 Billion KRW | 238.31% |
| 2010 Q1 | 15.57 Billion KRW | -4.49% |
| 2009 Q4 | 16.3 Billion KRW | 59.82% |
| 2009 FY | 49.46 Billion KRW | 50.21% |
| 2009 Q3 | 10.2 Billion KRW | 38.27% |
| 2009 Q2 | 7.37 Billion KRW | 0.0% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 FY | 32.93 Billion KRW | -44.14% |
| 2008 Q3 | 10.09 Billion KRW | -24.87% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 Q2 | 13.43 Billion KRW | 0.0% |
| 2008 Q4 | 5.7 Billion KRW | -43.46% |
| 2007 Q2 | 12.36 Billion KRW | 0.0% |
| 2007 FY | 58.94 Billion KRW | 21.49% |
| 2007 Q4 | 18.08 Billion KRW | 16.71% |
| 2007 Q3 | 15.49 Billion KRW | 25.39% |
| 2006 FY | 48.52 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 1652.755% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | -92.279% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 287.125% |
| HANDOK Inc. | -28.79 Billion KRW | 487.193% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 1425.007% |
| Yuhan Corporation | 93.5 Billion KRW | -19.241% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -902.492% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 549.386% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 23.75% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -3077.95% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 4548.658% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 5476.406% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 2564.217% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -399.274% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 1652.755% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 632.46% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -3011.644% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 194.278% |
| JW Holdings Corporation | 19.02 Billion KRW | -486.041% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 241.27% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 47.534% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -201.305% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 294.507% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -1721.401% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -6602.684% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -2127.922% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 1652.755% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | -201.637% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -201.305% |
| Yuhan Corporation | 93.5 Billion KRW | -19.241% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 786.176% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 2977.062% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -1722.155% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -201.305% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -489.776% |
| Korea United Pharm Inc. | 48.26 Billion KRW | -131.036% |
| CKD Bio Corp. | -24.19 Billion KRW | 560.894% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -366.204% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -306.373% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | -274.49% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 294.507% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | -137.2% |
| Boryung Corporation | 40.2 Billion KRW | -177.348% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 455.899% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 4548.658% |
| JW Lifescience Corporation | 28.14 Billion KRW | -296.184% |